Semen analysis and treatment risk factors in long-term survivors of childhood cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F21%3A10416581" target="_blank" >RIV/00064203:_____/21:10416581 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/21:10416581

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pn.1BuzS3b" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pn.1BuzS3b</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/and.13853" target="_blank" >10.1111/and.13853</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Semen analysis and treatment risk factors in long-term survivors of childhood cancer

Popis výsledku v původním jazyce

The objective of this study was to compare semen quality (sperm density, progressive motility and spermia) between long-term childhood cancer survivors and a control group of males. The second objective was to correlate the semen analysis of the survivors with cancer treatment and endocrine status. The semen quality of 143 survivors (median age, 23.6 years) was compared to 200 men (median age, 27.9 years) who had not been diagnosed with cancer. The cancer-related risk factors and gonadotrophin levels were compared. Overall, 65% of the survivors had abnormal semen analysis compared to 26.5% of the controls (p &lt; 0.0001). Survivors with nonaspermia had lower sperm density than the controls (p &lt; 0.001). Other observed correlations were not significant. Survivors who were treated with alkylating agents were more likely to have abnormal semen analysis (p &lt; 0.008). Follicle-stimulating hormone and luteinising hormone levels were significantly elevated (p &lt; 0.0001) in survivors with abnormal semen analysis. The semen quality parameters, except for low sperm density, did not differ in survivors with nonaspermia compared to the controls. The risk factors included treatment with alkylating agents. Elevated gonadotrophin levels correlated with abnormal semen analysis. All cancer survivors should be made aware of the possibility of suffering from cancer treatment-related infertility.

Název v anglickém jazyce

Semen analysis and treatment risk factors in long-term survivors of childhood cancer

Popis výsledku anglicky

The objective of this study was to compare semen quality (sperm density, progressive motility and spermia) between long-term childhood cancer survivors and a control group of males. The second objective was to correlate the semen analysis of the survivors with cancer treatment and endocrine status. The semen quality of 143 survivors (median age, 23.6 years) was compared to 200 men (median age, 27.9 years) who had not been diagnosed with cancer. The cancer-related risk factors and gonadotrophin levels were compared. Overall, 65% of the survivors had abnormal semen analysis compared to 26.5% of the controls (p &lt; 0.0001). Survivors with nonaspermia had lower sperm density than the controls (p &lt; 0.001). Other observed correlations were not significant. Survivors who were treated with alkylating agents were more likely to have abnormal semen analysis (p &lt; 0.008). Follicle-stimulating hormone and luteinising hormone levels were significantly elevated (p &lt; 0.0001) in survivors with abnormal semen analysis. The semen quality parameters, except for low sperm density, did not differ in survivors with nonaspermia compared to the controls. The risk factors included treatment with alkylating agents. Elevated gonadotrophin levels correlated with abnormal semen analysis. All cancer survivors should be made aware of the possibility of suffering from cancer treatment-related infertility.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NV19-03-00245" target="_blank" >NV19-03-00245: Známky urychleného stárnutí jako pozdní následek léčby pro nádory dětského věku a rizikový faktor sekundárních nádorů.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Andrologia

ISSN

0303-4569

e-ISSN

—

Svazek periodika

53

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

8

Strana od-do

e13853

Kód UT WoS článku

000578991200001

EID výsledku v databázi Scopus

2-s2.0-85092646905